ZK 304709
Alternative Names: ZK-304709Latest Information Update: 17 Mar 2010
At a glance
- Originator Bayer Schering Pharma
- Class Antineoplastics
- Mechanism of Action CDC2 protein kinase inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 4 inhibitors; Platelet-derived growth factor receptor antagonists; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG
- 05 May 2005 Phase-I clinical trials in Cancer in Germany (PO)